Table 1 Baseline patient and disease characteristics

From: Exposure-response analysis of rilotumumab in gastric cancer: the role of tumour MET expression

 

Placebo ( N =39)

Low rilotumumab exposurea (N =40)

High rilotumumab exposurea (N =41)

Overall ( N =120)

Disease stage, n (%)

Locally advancedb

5 (12.8)

8 (20.0)

5 (12.2)

18 (15.0)

Metastaticb

34 (87.2)

32 (80.0)

36 (87.8)

102 (85.0)

ECOG performance status, n (%)

0b

16 (41.0)

18 (45.0)

19 (46.3)

53 (44.2)

1b

23 (59.0)

22 (55.0)

22 (53.7)

67 (55.8)

Gender, n (%)

Male

31 (79.5)

28 (70.0)

28 (68.3)

87 (72.5)

Female

8 (20.5)

12 (30.0)

13 (31.7)

33 (27.5)

Weight (kg), mean (s.d.)

71.3 (14.4)

64.2 (17.1)

71.6 (15.8)

69.1 (16.0)

Age (years), mean (s.d.)

59.9 (9.3)

56.3 (13.2)

60.0 (11.5)

58.8 (11.5)

Liver metastasis, n (%)

18 (46.2)

17 (42.5)

16 (39.0)

51 (42.5)

Baseline laboratory values, mean (s.d.)

Total bilirubin (μmol l−1)

9.5 (4.0)

9.9 (6.0)

9.9 (5.6)

9.8 (5.2)

Alanine amino transferase (U l−1)

37.0 (38.6)

25.0 (22.4)

26.4 (26.2)

29.4 (30.0)

Aspartate amino transferase (U l−1)

35.4 (29.2)

31.9 (27.5)

31.3 (42.9)

32.8 (33.8)

Alkaline phosphatasec (U l−1)

216.4 (218.2)

204.4 (220.3)

244.8 (510.5)

221.9 (344.1)

Serum creatinine (μmol l−1)

73.1 (18.5)

73.1 (20.6)

70.7 (14.6)

72.3 (17.9)

Creatinine clearance (ml min−1)

1.6 (0.5)

3.3 (11.5)

3.9 (14.8)

3.0 (10.8)

Albumin (g l−1)

38.4 (5.6)

36.0 (6.0)

37.3 (5.5)

37.2 (5.7)

Blood urea nitrogen (mmol l−1)

6.2 (3.4)

4.8 (1.2)

4.7 (1.7)

5.4 (2.5)

Phosphorusd (mmol l−1)

1.1 (0.2)

1.2 (0.2)

1.2 (0.2)

1.2 (0.2)

Potassium (mmol l−1)

4.4 (0.4)

4.3 (0.5)

4.5 (0.5)

4.4 (0.5)

Red blood cellse (1012 per l)

4.5 (0.5)

4.2 (0.7)

4.4 (0.6)

4.4 (0.6)

Platelets (109 per l)

308.4 (100.4)

353.0 (141.1)

317.0 (115.0)

326.2 (120.7)

Absolute neutrophil count (109 per l)

5.5 (3.6)

6.5 (3.2)

6.3 (5.5)

6.1 (4.2)

White blood cells (109 per l)

8.0 (3.8)

9.2 (3.7)

8.9 (5.8)

8.7 (4.6)

Monocytes (109 per l)

0.6 (0.3)

0.6 (0.4)

0.6 (0.3)

0.6 (0.3)

Haematocrit

0.4 (0.0)

0.3 (0.0)

0.4 (0.0)

0.4 (0.0)

Haemoglobin (g l−1)

125.1 (14.0)

115.3 (14.5)

122.4 (16.0)

120.9 (15.3)

Lymphocytes (109 per l)

1.7 (0.7)

1.7 (0.7)

1.7 (0.9)

1.7 (0.8)

Tumour MET expressionf, n (%)

28 (71.8)

30 (75.0)

33 (80.5)

91 (75.8)

Positive

17 (43.6)

21 (52.5)

20 (48.8)

58 (48.3)

Negative

11 (28.2)

9 (22.5)

13 (31.7)

33 (27.5)

Missing

11 (28.2)

10 (25.0)

8 (19.5)

29 (24.2)

  1. Abbreviations: ECOG=Eastern Cooperative Oncology Group; MET=a symbol of gene with the official name of MET proto-oncogene, receptor tyrosine kinase.
  2. aPatients were divided into low and high rilotumumab exposure groups based on median Cminss, with low exposure defined as Cminss <94 μg ml−1 and high exposure defined as Cminss ⩾94 μg ml−1.
  3. bStratification factors defined by the rilotumumab phase 2 protocol for gastric cancer.
  4. cData were available for 38 patients in the placebo group, 40 patients in the low-exposure group, and 40 patients in the high-exposure group.
  5. dData were available for 38 patients in the placebo group, 38 patients in the low-exposure group, and 39 patients in the high-exposure group.
  6. eData were available for 38 patients in the placebo group, 40 patients in the low-exposure group, and 41 patients in the high-exposure group.
  7. fPatients were divided into positive and negative MET subgroups, with MET positivity defined as ⩾25% membranous staining of tumour cells at any intensity and MET negativity defined as <25% membranous staining.
Back to article page